Glukagon etkileşimleri

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Acute Pancreatitis Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with glucagon-like peptide-1 (GLP-1) receptor agonists, including BYETTA [see Adverse Reactions (6.2) ] . (Eksenatid etiketi, Uyarılar ve önlemler)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (Glukagon etiketi, İlaç etkileşimleri)

Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (Glukagon etiketi, İlaç etkileşimleri)

Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (Glukagon etiketi, İlaç etkileşimleri)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glukagon etiketi, İlaç etkileşimleri)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glukagon etiketi, İlaç etkileşimleri)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glukagon etiketi, İlaç etkileşimleri)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glukagon etiketi, İlaç etkileşimleri)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glukagon etiketi, İlaç etkileşimleri)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glukagon etiketi, İlaç etkileşimleri)

Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (Glukagon etiketi, İlaç etkileşimleri)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glukagon etiketi, İlaç etkileşimleri)

Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (Glukagon etiketi, İlaç etkileşimleri)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glukagon etiketi, İlaç etkileşimleri)

Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (Glukagon etiketi, İlaç etkileşimleri)

Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (Glukagon etiketi, İlaç etkileşimleri)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glukagon etiketi, İlaç etkileşimleri)

If the patient develops a substantial increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure. (Glukagon etiketi, Uyarılar ve önlemler)

Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (Glukagon etiketi, İlaç etkileşimleri)

The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics,… (Glimepirid etiketi, İlaç etkileşimleri)

…glucose-lowering effect of GLUCOTROL XL, leading to worsening glycemic control: atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol,… (Glipizid etiketi, İlaç etkileşimleri)

Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (Glukagon etiketi, İlaç etkileşimleri)

Indomethacin Clincial Impact: In patients taking indomethacin, GVOKE may lose its ability to raise blood glucose or may even produce hypoglycemia. (Glukagon etiketi, İlaç etkileşimleri)

Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (Glukagon etiketi, Uyarılar ve önlemler)

Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (Glukagon etiketi, Uyarılar ve önlemler)

Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (Glukagon etiketi, Uyarılar ve önlemler)

Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (Glukagon etiketi, Uyarılar ve önlemler)

Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (Glukagon etiketi, Uyarılar ve önlemler)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glukagon etiketi, İlaç etkileşimleri)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glukagon etiketi, İlaç etkileşimleri)

Hyperglycemia and Hypoglycemia Pharmacological studies in animals and humans show that lanreotide, like somatostatin and other somatostatin analogs, inhibits the secretion of insulin and glucagon. (Lanreotid etiketi, Uyarılar ve önlemler)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glukagon etiketi, İlaç etkileşimleri)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glukagon etiketi, İlaç etkileşimleri)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glukagon etiketi, İlaç etkileşimleri)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glukagon etiketi, İlaç etkileşimleri)

Hyperglycemia and Hypoglycemia MYCAPSSA alters the balance between the counter-regulatory hormones, insulin, glucagon, and growth hormone, which may result in hypoglycemia, or hyperglycemia, or diabetes mellitus. (Oktreotid etiketi, Uyarılar ve önlemler)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glukagon etiketi, İlaç etkileşimleri)

The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics,… (Pioglitazon ve glimepirid etiketi, İlaç etkileşimleri)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glukagon etiketi, İlaç etkileşimleri)

Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (Glukagon etiketi, Uyarılar ve önlemler)

Warfarin Clincial Impact: GVOKE and GVOKE Vial Dx may increase the anticoagulant effect of warfarin. (Glukagon etiketi, İlaç etkileşimleri)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glukagon etiketi, İlaç etkileşimleri)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glukagon etiketi, İlaç etkileşimleri)

Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, glucagon may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. (Glukagon etiketi, Uyarılar ve önlemler)

Intervention Monitor patients for unusual bruising or bleeding, as adjustments in warfarin dosage may be required. (Glukagon etiketi, İlaç etkileşimleri)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glukagon etiketi, Uyarılar ve önlemler)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glukagon etiketi, Uyarılar ve önlemler)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glukagon etiketi, Uyarılar ve önlemler)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glukagon etiketi, Uyarılar ve önlemler)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glukagon etiketi, Uyarılar ve önlemler)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glukagon etiketi, Uyarılar ve önlemler)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glukagon etiketi, Uyarılar ve önlemler)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glukagon etiketi, Uyarılar ve önlemler)

Glucagon-like peptide-1 (GLP-1) receptor agonists have induced thyroid C-cell adenomas and carcinomas in mice and rats at clinically relevant exposures. (Dulaglutid etiketi, Uyarılar ve önlemler)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glukagon etiketi, Uyarılar ve önlemler)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glukagon etiketi, Uyarılar ve önlemler)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glukagon etiketi, Uyarılar ve önlemler)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glukagon etiketi, Uyarılar ve önlemler)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glukagon etiketi, Uyarılar ve önlemler)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glukagon etiketi, Uyarılar ve önlemler)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glukagon etiketi, Uyarılar ve önlemler)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glukagon etiketi, Uyarılar ve önlemler)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glukagon etiketi, Uyarılar ve önlemler)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glukagon etiketi, Uyarılar ve önlemler)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glukagon etiketi, Uyarılar ve önlemler)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glukagon etiketi, Uyarılar ve önlemler)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glukagon etiketi, Uyarılar ve önlemler)

Examples: Atypical antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and… (Repaglinid etiketi, İlaç etkileşimleri)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glukagon etiketi, Uyarılar ve önlemler)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (Glukagon etiketi, Uyarılar ve önlemler)